Adjuvant use of antiprolactin, antiestrogen, and cytotoxic chemotherapy for breast cancer

Basit Öğe Kaydı
dc.authorid0000-0002-8335-1927en_US
dc.contributor.authorErkişi, Melek
dc.contributor.authorBurgut, Hüseyin Refik
dc.contributor.authorÜnsal, Mustafa
dc.contributor.authorİspir, Turgay
dc.contributor.authorVarinli, Seyhan
dc.contributor.authorKılıçoğlu, Remzi
dc.date.accessioned2024-07-12T21:03:09Z
dc.date.available2024-07-12T21:03:09Z
dc.date.issued1994en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractBetween September 1, 1985 and September 1, 1989, 110 premenopausal patients with estrogen-receptor-positive, stage-II breast cancer were randomized to receive, as adjuvant treatment following radiotherapy, either cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) + tamoxifen (T) + bromocriptine (B) bases or CMF + T only. Preoperative serum prolactin (PRL) levels or PRL-receptor status of the tumor were not available, but before the commencement of adjuvant therapy serum PRL levels were measured in all patients and found to be high in 28. The local (LR) and distant (DM) metastasis-recurrence rates were lower in patients given bromocriptine (CMF + T + B) (LR, 5.7%; DM, 10.9%) than in those not given bromocriptine (CMF + T) (LR, 10.9%; DM, 27.2%); these findings, however, were not significant (P > 0.05). In the 28 hyperprolactinemic patients the metastasis-recurrence rate (17/28) was higher (P = 0.0001) and disease-free survival was shorter (P = 0.001) than in the 80 normoprolactinemic patients. It was also demonstrated that the disease-free survival was longer (P = 0.009) and the metastasis-recurrence rate was lower (6/12) in hyperprolactinemic patients who received bromocriptine (CMF + T + B) than in hyperprolactinemic patients who did not (CMF + T) (11/16), while there was no difference in metastasis-recurrence rates and disease-free survival between the two treatment groups among normoprolactinemic patients. These results encourage further investigation of the action of bromocriptine adjuvant base. Baseline serum PRL measurement and tumor PRL-receptor determination could be valuable tools to identify the appropriate cases for antiprolactinemic treatment.en_US
dc.identifier.citationErkişi, M., Burgut, H. R., Ünsal, M., İspir, T., Varinli, S. ve Kılıçoğlu, R. (1994). Adjuvant use of antiprolactin, antiestrogen, and cytotoxic chemotherapy for breast cancer. Current Therapeutic Research. 55(1), s. 67-75.en_US
dc.identifier.endpage75en_US
dc.identifier.issn0011-393X
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage67en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0011393X05800785
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3639
dc.identifier.volume55en_US
dc.institutionauthorBurgut, Hüseyin Refik
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofCurrent Therapeutic Researchen_US
dc.relation.isversionof10.1016/S0011-393X(05)80078-5en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00594
dc.titleAdjuvant use of antiprolactin, antiestrogen, and cytotoxic chemotherapy for breast canceren_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu